ES002: Clinical-Stage Anti-CD39 Antibody with Best-in-Class Potential
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an excellent tolerability profile. ES002 has also shown superior enzymatic inhibition and binding affinity.
The ecto-ATPase CD39 is the rate-limiting enzyme in the ATP-adenosine pathway that plays an important immune regulatory role. The dual ES002 mechanism is designed to reverse immunosuppression by maintaining high levels of immune-stimulatory extracellular ATP while reducing suppressive adenosine. Blocking CD39 is expected to have a strong effect on the inhibition of Treg function, enhancing the killing function of effector T cells.
CD39 Dual ATP-Adenosine Mechanism of Action
In vitro and In vivo Properties
Anti-tumor activity in PBMC humanized mice
Statistically significant reduction in tumor volume observed in all groups treated with ES002 with a dose as low as 0.03mg/kg
The anti-tumor activity of an anti-CD39 antibody (ES002) in a multiple myeloma xenograft model is dependent on NK cells and myeloid cells. SITC 2021, P790